Markov Models: Overview Gerald F. Kominski, Ph.D. Professor, Department of Health Services.

Slides:



Advertisements
Similar presentations
Dealing with Uncertainty in Cost-Effectiveness Analyses
Advertisements

The Incorporation of Meta-Analysis Results into Evidence-Based Decision Modelling Nicola Cooper, Alex Sutton, Keith Abrams, Paul Lambert, David Jones Department.
Introduction to Medical Decision Making and Decision Analysis
What role should probabilistic sensitivity analysis play in SMC decision making? Andrew Briggs, DPhil University of Oxford.
An Introduction to Markov Decision Processes Sarah Hickmott
1 Cost-effectiveness analysis using Markov modeling Rahul Ganguly Ph.D. November 25 th, 2006 BITS, Pilani.
Nov M. Huang Northwestern Univ. 1 Markov Chain Population Models in Medical Decision Making Gordon Hazen Min Huang Northwestern University.
Operations Research: Applications and Algorithms
QUANTITATIVE RISK STRATIFICATION IN MARKOV CHAINS WITH QUASI-STATIONARY DISTRIBUTIONS David C Chan, MD, MSc 1 ; Philip K Pollett, PhD 2 ; Milton C Weinstein,
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Introduction to decision modelling Andrew Sutton.
Use of Bayesian Methods for Markov Modelling in Cost Effectiveness Analysis: An application to taxane use in advanced breast cancer Nicola Cooper, Keith.
Planning under Uncertainty
Lecture 13 – Continuous-Time Markov Chains
EXPECTED OUTCOMES The study will provide information on the impact of tobacco use on health from epidemiological, social and economic perspectives in relation.
Market Preferences and Process Selection (MAPPS): the Value of Perfect Flexibility Stephen Lawrence University of Colorado George Monahan University of.
Chapter 14 Simulation. Monte Carlo Process Statistical Analysis of Simulation Results Verification of the Simulation Model Computer Simulation with Excel.
Using ranking and DCE data to value health states on the QALY scale using conventional and Bayesian methods Theresa Cain.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
CS6800 Advanced Theory of Computation Fall 2012 Vinay B Gavirangaswamy
Lecture 11 – Stochastic Processes
Introduction to ModelingMonte Carlo Simulation Expensive Not always practical Time consuming Impossible for all situations Can be complex Cons Pros Experience.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.
Lecture 12 Monte Carlo Simulations Useful web sites:
A cost-effectiveness evaluation of preventive interventions for HIV-TB in Sub-Saharan Africa (Tanzania): Relevance for neurological infections Lucie Jean-Gilles.
Advanced methods of molecular dynamics Monte Carlo methods
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
University of Minnesota Medical Technology Evaluation and Market Research Course: MILI/PUBH 6589 Spring Semester, 2012 Stephen T. Parente, Ph.D. Carlson.
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
Introduction to TreeAge June 1, 2005 Mendel E. Singer, Ph.D. Case School of Medicine
Types of analysis. Simulation rationale u Each patient’s natural history is random, but guided by underlying parameters. u With sufficiently large number.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
SIMULATION USING CRYSTAL BALL. WHAT CRYSTAL BALL DOES? Crystal ball extends the forecasting capabilities of spreadsheet model and provide the information.
BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2,
1 Chapter 7 Applying Simulation to Decision Problems.
“Further Modeling Issues in Event History Analysis by Robert E. Wright University of Strathclyde, CEPR-London, IZA-Bonn and Scotecon.
Monté Carlo Simulation  Understand the concept of Monté Carlo Simulation  Learn how to use Monté Carlo Simulation to make good decisions  Learn how.
PHARMACOECONOMIC EVALUATIONS & METHODS MARKOV MODELING IN DECISION ANALYSIS FROM THE PHARMACOECONOMICS ON THE INTERNET ®SERIES ©Paul C Langley 2004 Maimon.
Simulation is the process of studying the behavior of a real system by using a model that replicates the system under different scenarios. A simulation.
DR AMER JAFAR ‘STROKE’ October Ethnicity and recurrence of stroke Population-based study Compared poststroke recurrence and survival in Mexican.
The generalization of Bayes for continuous densities is that we have some density f(y|  ) where y and  are vectors of data and parameters with  being.
Decision Theoretic Planning. Decisions Under Uncertainty  Some areas of AI (e.g., planning) focus on decision making in domains where the environment.
Single Ion Channels.
Age-from-stage theory What is the probability an individual will be in a certain state at time t, given initial state at time 0?
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
Brennan Spiegel, MD, MSHS
Introduction to decision analysis modeling Alice Zwerling, Postdoctoral fellow, JHSPH McGill TB Research Methods Course July 7, 2015.
Louisiana Department of Transportation and Development Forecasting Construction Cost Index Values Using Auto Regression Modeling Charles Nickel, P.E. Cost.
Stochastic Processes and Transition Probabilities D Nagesh Kumar, IISc Water Resources Planning and Management: M6L5 Stochastic Optimization.
Markov Decision Processes AIMA: 17.1, 17.2 (excluding ), 17.3.
Venture Capital and the Finance of Innovation [Course number] Professor [Name ] [School Name] Chapter 20 Monte Carlo Simulation.
Definition of the Hidden Markov Model A Seminar Speech Recognition presentation A Seminar Speech Recognition presentation October 24 th 2002 Pieter Bas.
Business Modeling Lecturer: Ing. Martina Hanová, PhD.
Alcohol and hospital admissions for injury and alcohol poisoning in West Sussex– a second order Monte Carlo simulation Ross Maconachie Public Health WSCC.
Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6): doi: /M
Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.
Cost effectiveness of AF monitoring strategies in a post-stroke population LAUREN E. CIPRIANO JEFF HEALEY OMAR AKHTAR KAREN LEE LUCIANO A. SPOSATO APRIL.
Copyright © 2009 American Medical Association. All rights reserved.
Business Modeling Lecturer: Ing. Martina Hanová, PhD.
Costs and Cost-Effectiveness of Adolescent Compliance with Treatment for Latent Tuberculosis Infection: Results from a Randomized Trial  Gerald F. Kominski,
V5 Stochastic Processes
Background & Objectives
Discrete-time markov chain (continuation)
Cost-Effectiveness of Helicopter Versus Ground Emergency Medical Services for Trauma Scene Transport in the United States  M. Kit Delgado, MD, MS, Kristan.
Erythropoietic Growth Factors for Treatment-Induced Anemia in Hepatitis C: A Cost- Effectiveness Analysis  Brennan M.R. Spiegel, Kristina Chen, Chiun–Fang.
Decision analysis to define the optimal management of athletes with anomalous aortic origin of a coronary artery  Carlos M. Mery, MD, MPH, Keila N. Lopez,
Discrete-time markov chain (continuation)
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost- effectiveness analysis  Mark D. Schleinitz, MS, MD, J.Peter Weiss, MS,
Zachary Blomme University of Nebraska, Lincoln Pattern Recognition
Presentation transcript:

Markov Models: Overview Gerald F. Kominski, Ph.D. Professor, Department of Health Services

Markov Models: Why Are They Necessary? n Conventional decision analysis models assume: -Chance events -Limited time horizon -Events that do not recur n What happens if we have a problem with: -An extended time horizon, say, over a lifetime -Events can reoccur throughout a lifetime

Decision Tree for Atrial Fibrillation

State-Transition Diagram for Atrial Fibrillation Well Post-StrokeDead p 12 =0.2 p 22 =0.9 p 33 =1.0 p 11 =0.7 p 23 =0.1 p 13 =0.1 The probabilities for all paths out of a state must sum to 1.0. Death is known as an absorbing state, because individuals who enter that state cannot transition out of it.

Transition Probabilities Well Post- Stroke Dead Well Dead State of Current Cycle State of Next Cycle Transition probabilities that remain constant over time are characteristic of stationary Markov models, aka Markov chains

Markov Model Definitions n Any process evolving over time with uncertainty is a stochastic process, and models based on such processes are stochastic or probabilistic models n If the process is both stochastic and the behavior of the model in one time period (i.e., cycle) does not depend on the previous time period, the process is Markovian -The process has “lack of memory” -Even processes where the previous state does matter can be made Markovian through definition of temporary states know as tunnel states

Tunnel States Well Post-Stoke 1 Post-Stroke 2Post-Stroke 3 Post-Stroke Dead

Defining a Markov Model n Define the initial states n Determine the cycle length n Consider possible transitions among states n Determine transition probabilities n Determine utilities, and costs (if cost-effectiveness analysis), for each state

Evaluating Markov Models: Cohort Simulation State CycleWell Post- Stroke Dead Sum of Years Lived Survival 010, ,0002,0001,0009, ,9003,2001,9008, ,4303,8602,7107, ,4014,1603,4396, ,6814,2244,0955, ,1764,1384,6865, ,9595,2174, , , The data in the last column is used to produce a survival curve, aka a Markov trace.

Estimating Markov Models: Monte Carlo Simulation n Instead of processing an entire cohort and applying probabilities to the cohort, simulate a large number (e.g., 10,000) cases proceeding through the transition matrix -Monte Carlo simulation -TreeAge will do this for you quickly, without programming n The advantage of this approach is that it provides estimates of variation around the mean n Monte Carlo simulation is most valuable because it permits efficient modeling of complex prior history -Such variables are known as tracker variables

Example of a 5-State Markov Source: Kominski GF, Varon SF, Morisky DE, Malotte CK, Ebin VJ, Coly A, Chiao C. Costs and cost- effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial. Journal of Adolescent Health 2007;40(1):61-68.

Key Assumptions of the Markov Model VariableValue (Range)Reference Efficacy of IPT0.85 ( )19 Cost of treating active TB$22,500 ($17,000-$30,000)17 Cost of IPTVaries by study group and whether 6-month IPT is completed Current study TB cases per 100, ( )20 TB case fatality rate (varies with age)17 All-cause mortality rate per 100, ,476 (varies with age)National Center for Health Statistics, 1999 mortality tables Hepatotoxicity of IPT (age<35, started IPT) (age<35, completed IPT) 21 Hepatitis fatality rate Cost of treating IPT-induced hepatitis $11,250 ($8,500-$15,000)Authors’ assumption QALY – Healthy1.00 ( )Authors’ assumption QALY – Positive Skin Test, but Incomplete IPT0.90 ( )Authors’ assumption QALY – Active TB0.50 ( )Harvard Center for Risk Analysis QALY – IPT-induced hepatitis0.75 ( )Harvard Center for Risk Analysis Discount rate0.03 ( )Panel on Cost-Effectiveness